A clear line cannot be drawn between well-differentiated and anaplastic astrocytomas, and a subset of low-grade tumors, histologically indistinguishable from the others, behaves similarly to anaplastic astrocytomas. The proliferative index could aid in the identification of this subgroup, for which a different therapeutic approach would be indicated.
Methods
We immunohistochemically evaluated the proliferating ceil nuclear antigen (PCNA) expression in 77 well-differentiated astrocytomas, since PCNA has been considered a good proliferation marker. The prognostic significance of PCNA labeling index (LI) was assessed in univariate and multivariate analysis, taking into consideration some clinical and histologic factors known to affect prognosis.
Results
PCNA immunostaining identified a subgroup of tumors, characterized by a LI > 5%, with a median survival close to that observed in anaplastic astrocytomas. The survival table of such a group was significantly different from that of the group with a lower LI (p = 0.0009). Multivariate analysis confirmed that PCNA-LI is an independent prognostic factor (p = 0.001).
Conclusion
These data suggest that PCNA immunostaining can be a useful tool to define the prognosis of low-grade astrocytomas on routine biopsy material.
AllegranzaA., GirlandoS., ArrigoniG.L., VeroneseS., MauriF.A., GambacortaM., PolloB., Dalla PalmaP., BarbareschiM.: Proliferating cell nuclear antigen expression in central nervous system neoplasm.Virchows Archiv. A. Pathol. Anat., 419: 417–423, 1991.
2.
BravoR., FranckR., BlundellP.A., MacDonald-BravoH.: Cyclin-PCNA is the auxilary protein of DNA polymerase-delta.Nature, 326: 515–517, 1987.
3.
BravoR., MacDonald-BravoH.: Existence of two populations of cyclin proliferating cell nuclear antigen during the cell cycle: association with DNA replication sites.J. Cell. Biol., 105: 1549–1554, 1990.
CelisJ.E., BravoR., LarsenP.M., FayS.J.: Cyclin: a nuclear protein whose levels correlates directly with the proliferative state of normal as well as transformed cells.Leuk. Res., 8: 143–146, 1984.
6.
CelisJ.E., CelisA.: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells-subdivision of S phase.Proc. Natl. Acad. Sci. USA, 82: 3262–3266, 1985.
7.
ColtreraM.D., GownA.M.: PCNA/Cyclin expression and BrdU uptake define different subpopulation in different cell lines.J. Histochem. Cytochem., 39: 23–30, 1991.
8.
FazekasJ.T.: Treatment of grades I and II astrocytomas. The role of radiotherapy.Int. J. Rad. Oncol. Biol. Phys., 2: 661–666, 1977.
9.
GarciaR.L., ColtreraM.D., GownA.M.: Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis.Am. J. Pathol., 134: 733–739, 1989.
10.
GolA.: A relatively benign astrocytoma of the cerebrum. A clinical study of 194 verified cases.J. Neurosurg., 18: 501–506, 1961.
11.
HallP.A., LevinsonD.A., WoodsA.L., YuC.C.W., KellockD.B., WatkinsJ.A., BarnesD.M., GillettC.E., CamplejohnsR., DoverR., WaseemN.H., LaneD.P.: Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms.J. Pathol., 162: 285–294, 1990.
12.
HoshinoT., WilsonC.B., EllisW.G.: Gemistocytic astrocytes in gliomas. An autoradiographic study.J. Neuropathol. Exp. Neurol., 34: 263–281, 1975.
13.
HoshinoT., WilsonC.B.: Cell kinetic analyses of human malignant brain tumors (gliomas).Cancer, 44: 956–962, 1979.
14.
HoshinoT., RodriguezL.A., ChoK.G., LeeK.S., WilsonC.B., EdwardsM.S., LevinV.A., DavisR.L.: Prognostic implications of the proliferative potential of low-grade astrocytomas.J. Neurosurg., 69: 839–842, 1988.
KurkiP., VanderlaanM., DolbeareF., GrayJ., TanE.M.: Expression of proliferating cell nuclear antigen (PCNA)/cyclin during cell cycle.Exp. Cell. Res., 166: 209–221, 1986.
19.
LawsE.R., TaylorW.F., CliftonM.B., OkazakiH.: Neurosurgical management of low-grade astrocyatoma of cerebral hemispheres.J. Neurosurg., 61: 665–673, 1984.
20.
LeibelL.A., ShelineG.E., WaraW.M., BoldreyE.B., NielsenS.L.: The role of radiation therapy in the treatment of astrocytomas.Cancer, 35: 1551–1557, 1975.
21.
LloverasB., EdgedonS., ThorA.D.: Evaluation of in vitro bromodoxyuridine labeling of breast carcinoma with the use of a commercial kit.Am. J. Clin. Pathol., 95: 41–47, 1991.
22.
LouisD.N., EdgertonS., ThjorA.D., Hedley-WhyteE.T.: Proliferating cell nuclear antigen and Ki-67 immunohistochemistry in brain tumors: a comparative study.Acta. Neuropathol., 65: 675–679, 1991.
23.
MedberyC.A., StrausK.L., SteinberS.M., CotelingamJ.D., FisherW.S.: Low-grade astrocytomas: treatment results and prognostic variables.Int. J. Radiation Oncol. Biol. Phys, 15: 837–841, 1988.
24.
MiuraM., DomonM., SasakiT., TakasakiY.: Induction of proliferating cell nuclear antigen (PCNA) complex formation in quiescent fibroblasts from a xeroderma pigmentosum patient.J. Cell. Physiol., 150: 370–376, 1992.
25.
MorimuraT., KitzK., BudkaH.: In situ analysis of cell kinetics in human brain tumors. A comparative immunocytochemical study of S phase cells by a new in vitro bromodeoxyuridine-labeling technique and of proliferating pool cells by monoclonal antibody Ki-67.Acta Neuropathol., 77: 276–282, 1989.
26.
NorthC.A., NorthR.B., EpsteinJ.A., PiantadosiS., WharamM.D.: Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy.Cancer, 66: 6–14, 1990.
27.
PiepmayerJ.M.: Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres.J. Neurosurg, 67: 177–181, 1987.
28.
RussellD.S., RubinsteinL.I.: Pathology of Tumors of the nervous System. Ed. n. 5, pp. 95–148, Arnold, London, 1989.
29.
SchifferD., ChiòA., GiordanaM.T., LeoneM., SoffiettiR.: Prognostic value of histologic factors in adult cerebral astrocytoma.Cancer, 61: 1386–1393, 1988.
30.
SchifferD., ChiòA., GiordanaM.T., PezzuloT., ViglianiM.C.: Proliferating cell nuclear antigen expression in brain tumors and its prognostic role in ependymonas: an immunohistochemical study.Acta Neuropathol., 85: 495–502, 1993.
ShivijM.K.K., KennyM.K., WoodH.D.: Proliferating cell nuclear antigen is required for DNA excision repair.Cell., 69: 367–374, 1992.
33.
SoffiettiR., ChiòA., GiordanaM.T., VasarioE., SchifferD.: Prognostic factors in well-differentiated cerebral astrocytomas in the adult.Neurosurgery, 24: 686–692, 1989.
34.
TheunissenP.H.M.H., BlaauwG.: Proliferating cell nuclear antigen immunostaining and survival in cerebral astrocytomas.Histopathology, 23: 75–79, 1993.
35.
ThorA.D., LloverasB.: How should bromodeoxyuridine labeling be counted? Am.J. Clin. Pathol., 96: 535–536, 1991.
36.
ViglianiM.C., BuffoA., CavallaP., ChiòA., GiordanaM.T., MarinoS., PezzuloT., SchifferD.: Proliferating cell nuclear antigen and MIB-1 in astrocytic tumors.Ital. J. Neurol. Sci., 14: 514, 1993.
37.
WeirB., GraceM.: The relative significance of factors affecting postoperative survival in astrocytomas, grade one and two.Can. J. Neurol., Sci., 3: 47–50, 1976.
38.
WhittonA.C., BloomH.J.G.: Low-grade glioma of the cerebral hemispheres in adults: a retrospective analysis of 88 cases.Int. J. Rad. Oncol. Biol. Phys., 18: 783–786, 1990.
